<DOC>
	<DOCNO>NCT02620774</DOCNO>
	<brief_summary>This study determine tissue penetration ceftolozane/tazobactam ( Zerbaxa , Merck &amp; Co. ) , novel β-lactam/β-lactamase combination antibiotic , extracellular , interstitial fluid soft tissue diabetic patient low limb wound infection . Penetration compare group healthy volunteer control participant .</brief_summary>
	<brief_title>Tissue Penetration Ceftolozane/Tazobactam Diabetic Patients With Lower Limb Infections</brief_title>
	<detailed_description>This study enroll 10 patient diabetes admit low limb wound infection 6 healthy volunteer control participant . The study take place inpatient unit Hartford Hospital patient Clinical Research Center Hartford Hospital healthy volunteer . All participant receive least 3 dos ceftolozane/tazobactam 1.5g every 8 hour . A microdialysis probe ( Mdialysis Inc. , N. Chelmsford MA ) insert subcutaneous soft tissue near margin wound ( patient ) thigh ( healthy volunteer ) . The microdialysis probe perfuse lactated Ringer 's solution sample collect hour 8 hour final dose . A peripheral intravenous catheter insert arm vein collect blood sample simultaneously microdialysis sample . Concentrations tissue compare blood determine percent penetration .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Wound Infection</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<mesh_term>Ceftolozane , tazobactam drug combination</mesh_term>
	<criteria>Experimental : Type 1 Type 2 diabetes mild moderate ( Grade 2 3 ) wound infection lower limb Active Comparator : Healthy Adult Volunteer All Participants : Less 18 year age History hypersensitivity ceftolozane/tazobactam , piperacillin/tazobactam , βlactam antibiotic History hypersensitivity lidocaine lidocaine derivative Females pregnant breastfeed Concomitant receipt βlactams antibiotic Concomitant receipt probenecid Reduced kidney function define creatinine clearance ≤ 50 mL/min Any reason felt investigator potentially affect outcome study Experimental Group Only : No palpable pedal pulse present Participants likely require multiple surgical intervention study period , therefore could affect placement microdialysis catheter Active Comparator Group Only : Positive urine drug screen ( cocaine , tetrahydrocannabinol , opiates , benzodiazepine , amphetamine ) History regular alcohol consumption exceed 7 drinks/week female 14 drinks/week men ( 1 drink = 5 ounce wine 12 ounce beer 1.5 ounce hard liquor ) within 6 month screen . Use tobacco nicotinecontaining product excess equivalence 5 cigarette per day . Use prescription nonprescription drug , vitamin , dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication , exception acetaminophen dose ≤ 1 g/day . Herbal supplement , hormonal method contraception ( include oral transdermal contraceptive , injectable progesterone , progestin subdermal implant , progesteronereleasing intrauterine device ( IUDs ) , postcoital contraceptive method ) , hormone replacement therapy must discontinue least 14 day prior first dose study medication . DepoProvera® must discontinue least 6 month prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>